Celldex Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CLDX | ABCL | ACRS | 8SJ.F | XNCR | QTTB | |
|---|---|---|---|---|---|---|
| Market cap | 2.35B | 3.98B | 570.34M | 1.84B | 2.60B | 267.03M |
| P/E (TTM) | — | — | — | — | — | 2.5 |
| Forward P/E | -7.0 | -16.1 | -5.1 | — | -9.9 | -8.8 |
| Price/book | 3.3 | 4.2 | 4.1 | 2.4 | 4.0 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +28.68% | +171.08% | +62.11% | −40.07% | +113.22% | +266.53% |
| Today | +0.74% | +0.82% | −1.60% | +1.70% | +14.33% | +2.40% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CLDX news ›Comparing Celldex Therapeutics (NASDAQ:CLDX) & Shattuck Labs (NASDAQ:STTK)
Posted by Michael Walen on Oct 26th, 2026 Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on First Tracks Biotherapeutics Inc, with a price target of $30.00. The company’s shares closed yesterday at $42.03. According to TipRanks, Archila is a…
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders.... Oct 12, 2026, 09:10 ET NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell &…
CellaVision AB: Latest Headlines - Nasdaq Stockholm Stock Exchange
Find the latest highlights on CellaVision AB at the Nasdaq Stockholm stock exchange. Advanced Medical Equipment & Technology All financial news and data tailored to specific country editions
DNB Carnegie raises price target for Cellavision to SEK 185 (180), reiterates buy
www.marketscreener.com Advanced Medical Equipment & Technology DNB Carnegie raises price target for Cellavision to SEK 185 (180), reiterates buy
Sangoma Technologies: Glazer Capital reports 5.3% stake
A manager and its managing member report a passive stake above 5% in Sangoma Technologies (SANG). Stock Titan - [SCHEDULE 13G] Sangoma Technologies Corp Passive Investment Disclosure (>5%) Sangoma Technologies: Glazer Capital reports 5.3%…
Celldex Therapeutics: Trying To Put Its Troubled History Behind It
(NASDAQ:CLDX) Seeking Alpha - Celldex Therapeutics remains a clinical-stage biotech focused on mast cell-driven diseases, with barzolvolimab as its lead candidate. - Recent Phase 3 barzolvolimab trials in chronic spontaneous urticari
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
Check Out Our Latest Analysis on SNDX Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company's research programs target biological…
Shenandoah Telecom: Dimensional reports 5.2% stake
A fund adviser reports a stake above 5% in Shenandoah Telecom (SHEN). Stock Titan - [SCHEDULE 13G] SHENANDOAH TELECOMMUNICATIONS CO/VA/ Passive Investment Disclosure (>5%) Shenandoah Telecom: Dimensional reports 5.2% stake The reported…
Celldex Therapeutics: FMR reports 10.7% stake
An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX). Stock Titan - [SCHEDULE 13G/A] Celldex Therapeutics, Inc. Amended Passive Investment Disclosure Celldex Therapeutics: FMR reports 10.7% stake…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com4
- stocktitan.net3
- marketscreener.com2
- defenseworld.net1
- marketbeat.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.